Canada NewsWire
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 3, 2016
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 3, 2016 /CNW/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its
third quarter 2016 financial results on Thursday, Nov. 10, 2016.
About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that
address treatment resistance in cancer patients. The company's lead compound, apatorsen (OGX-427), is designed to inhibit
production of Hsp27, disable cancer cells' defenses and overcome treatment resistance. Hsp27 is an intracellular protein that
protects cancer cells by helping them survive, leading to resistance and more aggressive cancer phenotypes. Both the potential
single-agent activity and synergistic activity of apatorsen with cancer treatments may increase the overall benefit of existing
therapies and augment the durability of treatment outcomes, which could lead to increased patient survival. More information is
available at www.OncoGenex.com and at the
company's Twitter account: https://twitter.com/OncoGenex_IR.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncogenex-to-report-third-quarter-2016-financial-results-on-nov-10-2016-300356903.html
SOURCE OncoGenex Pharmaceuticals, Inc.
